Brigatinib treated ALK positive lung squamous cell carcinoma after failed chemotherapy: A case report

Código QR

Brigatinib treated ALK positive lung squamous cell carcinoma after failed chemotherapy: A case report

Abstract The definitive efficacy of anaplastic lymphoma kinase (ALK) inhibitors in ALK positive lung squamous cell carcinoma (sqCC) patients remain unclear. Here, we report a case in which brigatinib had a therapeutic effect on ALK‐positive lung squamous cell carcinoma. The patient in this report wa...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Shuluan Li, Pei Zhang, Tianyu Wang, Jie Wang, Jianchun Duan
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	ALK brigatinib chemotherapy lung squamous cell carcinoma Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/0971c80435b5462b91fbf1f547730466
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Hypersensitivity in ALK-positive lung cancers exposed to ALK inhibitors: a case of successful switch to an alternative ALK inhibitor and systematic review of the literature
por: Deng L, et al.
Publicado: (2018)

Spotlight on brigatinib and its potential in the treatment of patients with metastatic ALK-positive non-small cell lung cancer who are resistant or intolerant to crizotinib
por: Jain RK, et al.
Publicado: (2017)

Efficacy and Drug Resistance Analysis of ALK Inhibitors in Combination with Stereotactic Body Radiation Therapy for Treating Lung Squamous Carcinoma Patient Harboring EML4-ALK Rearrangement
por: Liang L, et al.
Publicado: (2021)

Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations
por: Whitney E. Lewis, PharmD, et al.
Publicado: (2021)

Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer
por: Barrows SM, et al.
Publicado: (2019)

EFFICACY OF INDUCTION CHEMOTHERAPY IN LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF HEAD AND NECK
por: Muhammad Imran Khan Wajid, et al.
Publicado: (2019)

Outcomes and prognostic factors of chemotherapy for patients with locally advanced or metastatic pulmonary squamous cell carcinoma
por: Minami S, et al.
Publicado: (2016)

Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives
por: Giroux Leprieur E, et al.
Publicado: (2016)

Clinicopathological and prognostic implications of ALK rearrangement in patients with completely surgically resected lung adenocarcinoma
por: Huan Zhang, et al.
Publicado: (2021)

New Trend of Surgery in Locally Advanced Esophageal Squamous Cell Carcinoma Patients
por: Tatcha Rerkrak, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma
por: Hongfu Cai, et al.
Publicado: (2021)

ALK rearranged non–small cell lung carcinoma with EML4-NTRK3 fusion as a possible mechanism of resistance to third-generation ALK inhibitors
por: Elena Corral de la Fuente, et al.
Publicado: (2021)

Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study
por: Peng Yang, et al.
Publicado: (2021)

Neoadjuvant docetaxel, oxaliplatin plus S-1 for treating clinical stage III squamous cell carcinoma of the esophagus: Study protocol of an open-label phase II trial
por: Mitsuro Kanda, et al.
Publicado: (2021)

Role of afatinib in the treatment of advanced lung squamous cell carcinoma
por: Vavalà T
Publicado: (2017)

PD-1 inhibitors versus chemotherapy as second-line treatment for advanced esophageal squamous cell carcinoma: a meta-analysis
por: Xinxin Zhu, et al.
Publicado: (2021)

Real-world effectiveness of second-line Afatinib versus chemotherapy for the treatment of advanced lung squamous cell carcinoma in immunotherapy-naïve patients
por: You-Yi Chen, et al.
Publicado: (2021)

Acantholytic Squamous Cell Carcinoma
por: Sandy Maganito, et al.
Publicado: (2021)

A Clinical Scoring Model to Predict the Effect of Induction Chemotherapy With Definitive Concurrent Chemoradiotherapy on Esophageal Squamous Cell Carcinoma Prognosis
por: Yang Li, et al.
Publicado: (2021)

Gender specific eRNA TBX5-AS1 as the immunological biomarker for male patients with lung squamous cell carcinoma in pan-cancer screening
por: Tao Yan, et al.
Publicado: (2021)

Pigmented Squamous Cell Carcinoma: Is the Reported Prevalence Real?
por: Paola Corneli, et al.
Publicado: (2019)

Integrated analyses of copy number variations and gene differential expression in lung squamous-cell carcinoma
por: Yang,Zhao, et al.
Publicado: (2015)

Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Shinsuke Suzuki, et al.
Publicado: (2021)

Morphometric Analysis of Nucleus and Nucleolar Organizer Regions (NORs) in Tongue Squamous Cell Carcinoma (SCC)
por: Padovani,J. A. Jr., et al.
Publicado: (2007)

Well-Differentiated Squamous Cell Carcinoma: Is Histological Differentiation a Relevant Prognostic Parameter?
por: Iago Ferreira, et al.
Publicado: (2021)

Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials
por: Hao-chuan Ma, et al.
Publicado: (2021)

Prognostic Value of Preoperative Mean Platelet Volume and a Predictive Nomogram in Oral Squamous Cell Carcinoma Patients Based on Real-World Data
por: Ning Y, et al.
Publicado: (2021)

Identification and validation of an individualized prognostic signature of lung squamous cell carcinoma based on ferroptosis‐related genes
por: Xiayao Diao, et al.
Publicado: (2021)

Rectal Squamous Cell Carcinoma: A Case Report Of A Rare Histology
por: Sankal Psingh, et al.
Publicado: (2019)

Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the ALK Gene Have Durable Responses to ALK Kinase Inhibitors
por: Schrock AB, et al.
Publicado: (2020)

Pathological Complete Response to Neoadjuvant Chemotherapy in a Patient with HER2-Positive Squamous Cell Carcinoma of the Breast
por: Yuki Usui, et al.
Publicado: (2021)

Manejo clínico y terapéutico de un tumor fibroso pleural con translocación de ALK
por: Patricia Cruz-Castellanos, et al.
Publicado: (2021)

Death-Associated Protein Kinase is Underexpressed in High-Grade Oral Squamous Cell Carcinoma
por: Meneses,Ismário Silva de, et al.
Publicado: (2010)

Hypoxia-Targeting Multifunctional Nanoparticles for Sensitized Chemotherapy and Phototherapy in Head and Neck Squamous Cell Carcinoma
por: Song C, et al.
Publicado: (2020)

Significance of miR-141 and miR-340 in cervical squamous cell carcinoma
por: Li Wenting, et al.
Publicado: (2021)

Dramatic response to alectinib in a lung cancer patient with a novel VKORC1L1-ALK fusion and an acquired ALK T1151K mutation
por: Zhu VW, et al.
Publicado: (2018)

Two Cases of Squamous Cell Carcinoma of the Penis—A Dermoscopic View
por: Shekhar Neema, et al.
Publicado: (2020)

4NQO Carcinogenesis: A Model of Oral Squamous Cell Carcinoma
por: Rivera Martínez,César Andrés
Publicado: (2012)

Lack of relationship between cigarette smoking and alcohol use with dysplasia grade in ocular surface squamous neoplasia
por: Early AD, et al.
Publicado: (2018)

Oral and Oropharyngeal Squamous Cell Carcinoma in Our Population: The Clinic-Pathological and Morphological Description of 153 Cases
por: Agarwal,A. K, et al.
Publicado: (2011)